Anti-B. anthracis toxin Recombinant Antibody (24G4) (CAT#: MRO-093CT)

Figure 1 Domain-specific inhibition of antibody-mediated toxin neutralization by preincubation with PA or its amino-terminal fragment in a solid-phase ELISA.

Toxin-neutralizing antibodies were preincubated with a receptor-deficient mutant of PA (PArb−) or the amino-terminal 191 residues of PA expressed as a GFP fusion protein (PA₂₀-GFP) prior to their addition to the RAW267.4 cytotoxicity assay mixture. Open bars represent the degree of inhibition observed when antibodies were preincubated with PArb−. Filled bars represent inhibition by PA₂₀-GFP. Antibodies are grouped by their domain specificity.

Reason, D., Liberato, J., Sun, J., Keitel, W., & Zhou, J. (2009). Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infection and immunity, 77(5), 2030-2035.

Figure 2 Relative toxin-neutralizing ability of PA₆₃- or PA₂₀-specific antibodies.

CHO-derived human antibodies specific for PA were titrated in the RAW 264.7 cytotoxicity assay and the amount required to bring about 50% cell death determined. The median value for each group is indicated by a horizontal line. PA₆₃- and PA₂₀-specific antibodies differed significantly in the concentration required to effect 50% neutralization of LT (P = 0.01 by the Mann-Whitney U test).

Reason, D., Liberato, J., Sun, J., Keitel, W., & Zhou, J. (2009). Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed. Infection and immunity, 77(5), 2030-2035.

Figure 3 Dot blot assay of representative CHO cell-derived IgG1 PA-specific human monoclonal antibodies.

PA83 and PA63 were purchased from List Biological Laboratories. D4-GFP and PA20-GFP were expressed and purified from E. coli as described in the materials and methods section. All antigens were spotted at 1 µg per spot using a 96 well manifold. Blots were cut into strips and probed with individual PA-specific monoclonal antibodies.

Reason, D. C., Ullal, A., Liberato, J., Sun, J., Keitel, W., & Zhou, J. (2008). Domain specificity of the human antibody response to Bacillus anthracis protective antigen. Vaccine, 26(32), 4041-4047.